AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|
21.1 C
New York
Friday, November 6, 2026

Tag: plans

newsFORsourcecompanycontentinformationreleases1market

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

Cheap AI Bots Eye Junior Coders’ Lunch

In 2007, Luke Arrigoni pulled in $63,000 as a junior software developer. Fast forward to today, and AI tools that supposedly churn out better...

Gold Coast Health Plan Denounces Sharing of Medicaid Enrollment Data with Department of Homeland Security

CAMARILLO, Calif., June 14, 2025 /PRNewswire/ -- Gold Coast Health Plan (GCHP), the local Medi-Cal plan for Ventura County, is deeply concerned about the...

A.I. Saves Ad Industry—Until It Doesn’t.

The Cannes Lions Festival of Creativity, a glorified playground for ad executives who enjoy sipping overpriced cocktails while convincing themselves they're the maestros of...

SL Benfica President Rui Costa Inaugurates Portuguese club’s new Residential Academy in Florida

The "Eagles" have taken their world-famous player development methodology to the United States TAMPA, Fla., June 14, 2025 /PRNewswire/ -- SL Benfica President Rui Costa...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

PFMCrypto’s “1-Day Mining Contract” Sales Surge 76% – $1 Million Giveaway Ignites Community Buzz

As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users 
As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users

ELV SHAREHOLDERS: Elevance Health, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 11 Deadline (NYSE:ELV)

Elevance Health, Inc. investors that lost money are notified to contact BFA Law before July 11, 2025 securities fraud class action deadline.

CIVI SHAREHOLDERS: Civitas Resources, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 1 Deadline (NYSE:CIVI)

Civitas Resources, Inc. investors that lost money are notified to contact BFA Law before July 1, 2025 securities fraud class action deadline.

Zinemx Exchange: Upgrading Operational Management System and Building an International Team

DENVER, June 14, 2025 (GLOBE NEWSWIRE) -- Amid the trend of mainstream financial institutions restructuring their human resources systems, Zinemx Exchange has drawn on industry experience to complete a team restructuring and further optimize its operational management system, accelerating its expansion into international markets. David Reynolds, Founder and CEO of Zinemx, emphasized that an efficient team and a compliant management system are essential, and that the new operational structure will provide strong support for the international development of the platform.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlans

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers